Recent News

• 03.27.2025 - BeyondSpring Files 2024 Annual Report on Form 10-K
• 03.27.2025 - BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones
• 01.28.2025 - BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies
• 01.28.2025 - BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies
• 11.11.2024 - BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting
• 11.11.2024 - BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting

Recent Filings

• 02.25.2025 - EX-99.1 EX-99.1
• 02.25.2025 - 8-K Current report
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.28.2025 - 8-K Current report
• 01.28.2025 - EX-99.1 EX-99.1
• 01.03.2025 - 8-K Current report
• 12.31.2024 - 3 Initial statement of beneficial ownership of securities
• 12.31.2024 - 3 Initial statement of beneficial ownership of securities
• 12.31.2024 - 3 Initial statement of beneficial ownership of securities
• 12.31.2024 - 3 Initial statement of beneficial ownership of securities